
Travoprost monotherapy effective for POAG
Travoprost monotherapy has demonstrated long-term 24-hour efficacy for the treatment of primary open-angle glaucoma (POAG).
Travoprost monotherapy has demonstrated long-term 24-hour efficacy for the treatment of primary open-angle glaucoma (POAG).
In a 5-year study reported in the
All patients received a pre-treatment 24-hour IOP evaluation, followed by a series of 5 follow-up 24-hour evaluations at 12-month intervals throughout the trial.
In the 34 patients who completed the study, the travoprost monotherapy reduced the mean 24-hour IOP from 23.4 (±1.7) mmHg at baseline to the following:
- 16.8 (±2.4) mmHg at the 1-year assessment, a 28.4% decrease in IOP from baseline.
- 16.8 (±2.5) mmHg at the 2-year assessment (-28.1% from baseline)
- 16.8 (±2.4) mmHg at the 3-year assessment (-28.5% from baseline)
- 16.7 (±2.5) mmHg at the 4-year assessment (-28.6% from baseline)
- 16.9 (±2.4) mmHg at the 5-year assessment (-27.8% from baseline)
To read an abstract of the study, click
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
















































